A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Bristol-Myers Squibb
Bristol-Myers Squibb
Artiva Biotherapeutics, Inc.
University of Chicago
University of California, San Diego
Celgene
Eli Lilly and Company
Washington University School of Medicine
Acerta Pharma BV
National Institutes of Health Clinical Center (CC)
First Affiliated Hospital of Zhejiang University
Indapta Therapeutics, INC.
Gilead Sciences
City of Hope Medical Center
Aprea Therapeutics
ImmunityBio, Inc.
Cyteir Therapeutics, Inc.
Altor BioScience
Nordic Nanovector
Takeda
City of Hope Medical Center
University of Nebraska
Celgene
University of Nebraska
Hoffmann-La Roche
University Hospital Southampton NHS Foundation Trust
Genentech, Inc.
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Northwestern University
AbbVie
La Raza Medical Center
Weill Medical College of Cornell University
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
GC Cell Corporation
Hoffmann-La Roche
Hoffmann-La Roche
M.D. Anderson Cancer Center
Acrotech Biopharma Inc.
National Cancer Institute (NCI)
OHSU Knight Cancer Institute
Northwestern University
Weill Medical College of Cornell University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Masonic Cancer Center, University of Minnesota
Roswell Park Cancer Institute
Western Regional Medical Center
University of Washington
Mayo Clinic
National University Hospital, Singapore
Mayo Clinic